Morbidity, mortality and long term survival in patients with vascular resection in pancreatic cancer – single center experience

Abstract

Although venous resection in pancreatic cancer is widely used method, recently published data about its safety and survival benefit showed conflicting results. A retrospective case matched study was performed to compare the results of patients who underwent venous resection to those with no venous resection during radical surgery in pancreatic cancer.From January 2010 to December 2015, 297 pancreatic resections due to pancreatic tumor were performed in the National Cancer Institute (NCI). Fifty-three patients with venous resection were identified and enrolled into the study and matched with 66 patients without vascular resection during radical resection of pancreatic head/body cancer. Both groups matched for age, ASA score, need for preoperative biliary drainage and clinical staging of the tumor. Morbidity was determined according Clavien and Dindo classification [1] and was similar in both groups of patients (p = 0.48). Thirty day postoperative mortality was also equal in both groups 5.6 vs 4.5% (p > 0.99) and long term survival was with no significant difference. Median overall survival was 18.8 vs 20.7 months (p = 0.33) for patients with/without venous resection.Therefore we consider venous resection in pancreatic cancer safe procedure with equal morbidity and perioperative mortality as in patients with no need for vascular resection and with the same long term survival if R0 resection is achieved.

Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer Locations

“…different. Secondly, tumor size, LNR, tumor differentiation degree, nerve invasion, and distant metastasis were all independent prognostic factors both for PHC and PBTC, which was consistent with previous reports (34)(35)(36)(37). Third, the LNR in both groups exhibited independent predictive significance while LNM not.…”

Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

“…For patients with RPC or BRPC, vascular resection with concomitant reconstruction is widely used to attain negative margins during the pancreatic resection. Currently, pancreaticoduodenectomy combined with venous resection is proved to be safe and feasible and has the same long-term survival if R0 resection can be achieved [43–45]. Our subgroup analysis further found RPC + BRPC patients with a higher baseline proportion of vascular resection tended to show more survival benefits for NAC(R)T over SF (> 75% of vascular resection vs ≤ 35% of vascular resection; HR, 0.57 vs 0.77, respectively).…”